SlideShare ist ein Scribd-Unternehmen logo
1 von 16
CISPLATIN Terry Clayton Biological Inorganic Chemistry April 1, 2007
Outline ,[object Object],[object Object],[object Object],[object Object],[object Object]
Discovery ,[object Object],[object Object],[object Object],Nature   205 , 698 - 699 (13 February 1965); doi:10.1038/205698a0  Inhibition of Cell Division in  Escherichia coli  by Electrolysis Products from a Platinum Electrode BARNETT ROSENBERG, LORETTA VAN CAMP & THOMAS KRIGAS Biophysics Department, Michigan State University, East Lansing.
Chemotherapeutic agents for Oncology ,[object Object],[object Object],[object Object],[object Object]
Results! ,[object Object],[object Object],[object Object],J. Med. Chem. 2004, 47, 761-763. ,[object Object],[object Object],[object Object],[object Object],[object Object],Side Effects Nature, 1969, 222, 385-387.
Cisplatin Synthesis Dhara, S.C., A Rapid Method for the Synthesis of cis-[Pt(NH3)2Cl2], Indian Journal of Chemistry, vol. 8, No. 2, Feb. 1970, pp. 193-194.
F. Coste, J. M. Malinge, L. Serre, W. Shepard, M. Roth, M. Leng and C. Zelwer, "Crystal structure of a double-stranded DNA containing a cisplatin interstrand cross-link at 1.63 A resolution: hydration at the platinated site",  Nucleic Acids Res , 1999,  27 , 1837
Structural Requirement ,[object Object],[object Object],[object Object],Reedijk (2003) Proc. Natl. Acad. Sci. USA, 100.(7), 3611-3616.
Sites for Pt binding J. Chem. Ed. 83, 5, 2006 ,[object Object],[object Object]
Mechanism? ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],J. Am. Chem. Soc. 2001, 123, 3171-3172 J. Am. Chem. Soc. 2005, 127, 12768-12769
Why not trans? ,[object Object],[object Object],[object Object],[object Object],1:  Eur J Cancer. 1997 Oct;33(11):1823-8  ,[object Object],[object Object]
Analogues ,[object Object],Carboplatin Oxaliplatin Nedaplatin ,[object Object],[object Object]
Future ,[object Object],[object Object],[object Object],Bis(aceto)(1-adamantylamine)aminedichloroplatinum J. Med. Chem., 2004, 47, 761-763
Cytotoxicity Cisplatin-Resistant Tumor Lines   IC 50  ( µM) Cancer cell line cisplatin 1 Chronic myelogenous leukemia K562 >80 3 Chronic myelogenous leukemia KG-1 48 2 Acute myelogenous leukemia ML-2 >80 1 Mouse melanoma  B16 >80 6 Colon cancer HT-29N >80 12 Colon cancer HT29 50 8 Colon cancer HCT116 >80 9 Lung carcinoma A427 63 6 Breast carcinoma HBL100 63 6 Breast carcinoma MCF-7 71 8 Lung carcinoma CORL23/CTR >80 25 Ovarian carcinoma A2780 4 4 Ovarian carcinoma A2780/cis 40 3 Ovarian carcinoma A2780/cis90 >80 7
Questions
Thank You

Weitere ähnliche Inhalte

Was ist angesagt?

Reserpine structural elucidation
Reserpine structural elucidationReserpine structural elucidation
Reserpine structural elucidationDrSSreenivasa
 
Cisplatin,Doxorubicin,Tricyclic antidepressants
Cisplatin,Doxorubicin,Tricyclic antidepressantsCisplatin,Doxorubicin,Tricyclic antidepressants
Cisplatin,Doxorubicin,Tricyclic antidepressantsMompati Letsweletse
 
Lanthanide shift reagents in nmr
Lanthanide shift reagents in nmrLanthanide shift reagents in nmr
Lanthanide shift reagents in nmrDongguk University
 
Organometallic compounds in oncology : CISPLATIN
Organometallic compounds in oncology : CISPLATINOrganometallic compounds in oncology : CISPLATIN
Organometallic compounds in oncology : CISPLATINRANA SAHA
 
SMILES REARRANGEMENT [REACTION AND MECHANISM]
SMILES REARRANGEMENT [REACTION AND MECHANISM]SMILES REARRANGEMENT [REACTION AND MECHANISM]
SMILES REARRANGEMENT [REACTION AND MECHANISM]Shikha Popali
 
Alkylating anticancers
Alkylating anticancersAlkylating anticancers
Alkylating anticancersnoody4ever
 
Microwave assisted reactions
Microwave assisted reactionsMicrowave assisted reactions
Microwave assisted reactionsMohammadHaider18
 
Chapter 24 tyrosine kinase inhibitors
Chapter 24 tyrosine kinase inhibitorsChapter 24 tyrosine kinase inhibitors
Chapter 24 tyrosine kinase inhibitorsNilesh Kucha
 
APPLICATIONS OF ESR SPECTROSCOPY TO METAL COMPLEXES
APPLICATIONS OF ESR SPECTROSCOPY TO METAL COMPLEXESAPPLICATIONS OF ESR SPECTROSCOPY TO METAL COMPLEXES
APPLICATIONS OF ESR SPECTROSCOPY TO METAL COMPLEXESSANTHANAM V
 
Basic concept of radiation, radioactivity, radiation dose
Basic concept of radiation,  radioactivity, radiation doseBasic concept of radiation,  radioactivity, radiation dose
Basic concept of radiation, radioactivity, radiation dosemahbubul hassan
 
Metal complexes in therapeutic use of non chelated compounds
Metal complexes in therapeutic use of non chelated compoundsMetal complexes in therapeutic use of non chelated compounds
Metal complexes in therapeutic use of non chelated compoundssanjeevani kashyap
 
Natural products as leads for new pharmaceuticals
Natural products as leads  for new pharmaceuticalsNatural products as leads  for new pharmaceuticals
Natural products as leads for new pharmaceuticalsShikha Popali
 

Was ist angesagt? (20)

Reserpine structural elucidation
Reserpine structural elucidationReserpine structural elucidation
Reserpine structural elucidation
 
Cisplatin,Doxorubicin,Tricyclic antidepressants
Cisplatin,Doxorubicin,Tricyclic antidepressantsCisplatin,Doxorubicin,Tricyclic antidepressants
Cisplatin,Doxorubicin,Tricyclic antidepressants
 
Lanthanide shift reagents in nmr
Lanthanide shift reagents in nmrLanthanide shift reagents in nmr
Lanthanide shift reagents in nmr
 
Organometallic compounds in oncology : CISPLATIN
Organometallic compounds in oncology : CISPLATINOrganometallic compounds in oncology : CISPLATIN
Organometallic compounds in oncology : CISPLATIN
 
SMILES REARRANGEMENT [REACTION AND MECHANISM]
SMILES REARRANGEMENT [REACTION AND MECHANISM]SMILES REARRANGEMENT [REACTION AND MECHANISM]
SMILES REARRANGEMENT [REACTION AND MECHANISM]
 
Alkylating anticancers
Alkylating anticancersAlkylating anticancers
Alkylating anticancers
 
Anticancer Activity of Metal Complexes.pptx
Anticancer Activity of Metal Complexes.pptxAnticancer Activity of Metal Complexes.pptx
Anticancer Activity of Metal Complexes.pptx
 
Microwave assisted reactions
Microwave assisted reactionsMicrowave assisted reactions
Microwave assisted reactions
 
Chapter 24 tyrosine kinase inhibitors
Chapter 24 tyrosine kinase inhibitorsChapter 24 tyrosine kinase inhibitors
Chapter 24 tyrosine kinase inhibitors
 
Copper in proteins and enzymes
Copper in proteins and enzymesCopper in proteins and enzymes
Copper in proteins and enzymes
 
APPLICATIONS OF ESR SPECTROSCOPY TO METAL COMPLEXES
APPLICATIONS OF ESR SPECTROSCOPY TO METAL COMPLEXESAPPLICATIONS OF ESR SPECTROSCOPY TO METAL COMPLEXES
APPLICATIONS OF ESR SPECTROSCOPY TO METAL COMPLEXES
 
Zingiberene [Best one]
Zingiberene [Best one]Zingiberene [Best one]
Zingiberene [Best one]
 
Calixarenes
CalixarenesCalixarenes
Calixarenes
 
Basic concept of radiation, radioactivity, radiation dose
Basic concept of radiation,  radioactivity, radiation doseBasic concept of radiation,  radioactivity, radiation dose
Basic concept of radiation, radioactivity, radiation dose
 
Anticancer drugs
Anticancer drugsAnticancer drugs
Anticancer drugs
 
Metal complexes in therapeutic use of non chelated compounds
Metal complexes in therapeutic use of non chelated compoundsMetal complexes in therapeutic use of non chelated compounds
Metal complexes in therapeutic use of non chelated compounds
 
Natural products as leads for new pharmaceuticals
Natural products as leads  for new pharmaceuticalsNatural products as leads  for new pharmaceuticals
Natural products as leads for new pharmaceuticals
 
Carbenes .......
Carbenes .......Carbenes .......
Carbenes .......
 
Anticancer DRUG
Anticancer DRUG Anticancer DRUG
Anticancer DRUG
 
ETOPOSIDE & TENIPOSIDE
ETOPOSIDE & TENIPOSIDEETOPOSIDE & TENIPOSIDE
ETOPOSIDE & TENIPOSIDE
 

Ähnlich wie Cisplatin

Cancer Cells and anticancer effect of some plants and materials
Cancer Cells and anticancer effect of some plants and materialsCancer Cells and anticancer effect of some plants and materials
Cancer Cells and anticancer effect of some plants and materialsMaryam Yekefallah
 
MCO 2011 - Slide 30 - K. Öberg - Spotlight session - Neuroendocrine tumours
MCO 2011 - Slide 30 - K. Öberg - Spotlight session - Neuroendocrine tumoursMCO 2011 - Slide 30 - K. Öberg - Spotlight session - Neuroendocrine tumours
MCO 2011 - Slide 30 - K. Öberg - Spotlight session - Neuroendocrine tumoursEuropean School of Oncology
 
Metastatic bone disease: An old dogma and a new insight
Metastatic bone disease: An old dogma and a new insightMetastatic bone disease: An old dogma and a new insight
Metastatic bone disease: An old dogma and a new insightMohamed Abdulla
 
Neuroendocrine Tumors in 2019
Neuroendocrine Tumors in 2019Neuroendocrine Tumors in 2019
Neuroendocrine Tumors in 2019Mohamed Abdulla
 
New developments of targeted therapy in nsclc
New developments of targeted therapy in nsclcNew developments of targeted therapy in nsclc
New developments of targeted therapy in nsclclihua jiao
 
Targeted therapy and immunotherapy in lung cancer
Targeted therapy and immunotherapy in lung cancerTargeted therapy and immunotherapy in lung cancer
Targeted therapy and immunotherapy in lung cancerAlok Gupta
 
5943408.ppt
5943408.ppt5943408.ppt
5943408.ppttttran
 
Gene Profiling in Clinical Oncology - Slide 4 - L. Lacroix - New markers to d...
Gene Profiling in Clinical Oncology - Slide 4 - L. Lacroix - New markers to d...Gene Profiling in Clinical Oncology - Slide 4 - L. Lacroix - New markers to d...
Gene Profiling in Clinical Oncology - Slide 4 - L. Lacroix - New markers to d...European School of Oncology
 
A. Shamseddine - Prostate and renal cancer - State of the art and update on s...
A. Shamseddine - Prostate and renal cancer - State of the art and update on s...A. Shamseddine - Prostate and renal cancer - State of the art and update on s...
A. Shamseddine - Prostate and renal cancer - State of the art and update on s...European School of Oncology
 
Present and Future Impact of Cytogenetics on Acute Myeloid Leukemia
Present and Future Impact of Cytogenetics on Acute Myeloid LeukemiaPresent and Future Impact of Cytogenetics on Acute Myeloid Leukemia
Present and Future Impact of Cytogenetics on Acute Myeloid Leukemialarriva
 
4 ΣΥΜΠΟΣΙΟ ΚΛΙΝΙΚΗΣ ΟΓΚΟΛΟΓΙΑΣ ΡΟΔΟΥ: Εξελίξεις στη θεραπεία του πλακώδους κα...
4 ΣΥΜΠΟΣΙΟ ΚΛΙΝΙΚΗΣ ΟΓΚΟΛΟΓΙΑΣ ΡΟΔΟΥ: Εξελίξεις στη θεραπεία του πλακώδους κα...4 ΣΥΜΠΟΣΙΟ ΚΛΙΝΙΚΗΣ ΟΓΚΟΛΟΓΙΑΣ ΡΟΔΟΥ: Εξελίξεις στη θεραπεία του πλακώδους κα...
4 ΣΥΜΠΟΣΙΟ ΚΛΙΝΙΚΗΣ ΟΓΚΟΛΟΓΙΑΣ ΡΟΔΟΥ: Εξελίξεις στη θεραπεία του πλακώδους κα...isrodoy isr
 
Actualización en el abordaje terapéutico ante un cáncer colorrectal metastásico
Actualización en el abordaje terapéutico ante un cáncer colorrectal metastásicoActualización en el abordaje terapéutico ante un cáncer colorrectal metastásico
Actualización en el abordaje terapéutico ante un cáncer colorrectal metastásicoMauricio Lema
 
Gastrointestinal stromal tumors (GIST).pptx
Gastrointestinal stromal tumors (GIST).pptxGastrointestinal stromal tumors (GIST).pptx
Gastrointestinal stromal tumors (GIST).pptxSujan Shrestha
 

Ähnlich wie Cisplatin (20)

CRPC management
CRPC managementCRPC management
CRPC management
 
Cancer Cells and anticancer effect of some plants and materials
Cancer Cells and anticancer effect of some plants and materialsCancer Cells and anticancer effect of some plants and materials
Cancer Cells and anticancer effect of some plants and materials
 
MCO 2011 - Slide 30 - K. Öberg - Spotlight session - Neuroendocrine tumours
MCO 2011 - Slide 30 - K. Öberg - Spotlight session - Neuroendocrine tumoursMCO 2011 - Slide 30 - K. Öberg - Spotlight session - Neuroendocrine tumours
MCO 2011 - Slide 30 - K. Öberg - Spotlight session - Neuroendocrine tumours
 
targeted therapy
targeted therapytargeted therapy
targeted therapy
 
Metastatic bone disease: An old dogma and a new insight
Metastatic bone disease: An old dogma and a new insightMetastatic bone disease: An old dogma and a new insight
Metastatic bone disease: An old dogma and a new insight
 
Neuroendocrine Tumors in 2019
Neuroendocrine Tumors in 2019Neuroendocrine Tumors in 2019
Neuroendocrine Tumors in 2019
 
Dr. Goy MCL
Dr. Goy MCLDr. Goy MCL
Dr. Goy MCL
 
New developments of targeted therapy in nsclc
New developments of targeted therapy in nsclcNew developments of targeted therapy in nsclc
New developments of targeted therapy in nsclc
 
Targeted therapy and immunotherapy in lung cancer
Targeted therapy and immunotherapy in lung cancerTargeted therapy and immunotherapy in lung cancer
Targeted therapy and immunotherapy in lung cancer
 
5943408.ppt
5943408.ppt5943408.ppt
5943408.ppt
 
7 capdevila
7 capdevila7 capdevila
7 capdevila
 
Gene Profiling in Clinical Oncology - Slide 4 - L. Lacroix - New markers to d...
Gene Profiling in Clinical Oncology - Slide 4 - L. Lacroix - New markers to d...Gene Profiling in Clinical Oncology - Slide 4 - L. Lacroix - New markers to d...
Gene Profiling in Clinical Oncology - Slide 4 - L. Lacroix - New markers to d...
 
A. Shamseddine - Prostate and renal cancer - State of the art and update on s...
A. Shamseddine - Prostate and renal cancer - State of the art and update on s...A. Shamseddine - Prostate and renal cancer - State of the art and update on s...
A. Shamseddine - Prostate and renal cancer - State of the art and update on s...
 
Present and Future Impact of Cytogenetics on Acute Myeloid Leukemia
Present and Future Impact of Cytogenetics on Acute Myeloid LeukemiaPresent and Future Impact of Cytogenetics on Acute Myeloid Leukemia
Present and Future Impact of Cytogenetics on Acute Myeloid Leukemia
 
4 ΣΥΜΠΟΣΙΟ ΚΛΙΝΙΚΗΣ ΟΓΚΟΛΟΓΙΑΣ ΡΟΔΟΥ: Εξελίξεις στη θεραπεία του πλακώδους κα...
4 ΣΥΜΠΟΣΙΟ ΚΛΙΝΙΚΗΣ ΟΓΚΟΛΟΓΙΑΣ ΡΟΔΟΥ: Εξελίξεις στη θεραπεία του πλακώδους κα...4 ΣΥΜΠΟΣΙΟ ΚΛΙΝΙΚΗΣ ΟΓΚΟΛΟΓΙΑΣ ΡΟΔΟΥ: Εξελίξεις στη θεραπεία του πλακώδους κα...
4 ΣΥΜΠΟΣΙΟ ΚΛΙΝΙΚΗΣ ΟΓΚΟΛΟΓΙΑΣ ΡΟΔΟΥ: Εξελίξεις στη θεραπεία του πλακώδους κα...
 
Prostate cancer
Prostate cancer   Prostate cancer
Prostate cancer
 
PhD
PhDPhD
PhD
 
Actualización en el abordaje terapéutico ante un cáncer colorrectal metastásico
Actualización en el abordaje terapéutico ante un cáncer colorrectal metastásicoActualización en el abordaje terapéutico ante un cáncer colorrectal metastásico
Actualización en el abordaje terapéutico ante un cáncer colorrectal metastásico
 
Prostate 101
Prostate 101Prostate 101
Prostate 101
 
Gastrointestinal stromal tumors (GIST).pptx
Gastrointestinal stromal tumors (GIST).pptxGastrointestinal stromal tumors (GIST).pptx
Gastrointestinal stromal tumors (GIST).pptx
 

Cisplatin

  • 1. CISPLATIN Terry Clayton Biological Inorganic Chemistry April 1, 2007
  • 2.
  • 3.
  • 4.
  • 5.
  • 6. Cisplatin Synthesis Dhara, S.C., A Rapid Method for the Synthesis of cis-[Pt(NH3)2Cl2], Indian Journal of Chemistry, vol. 8, No. 2, Feb. 1970, pp. 193-194.
  • 7. F. Coste, J. M. Malinge, L. Serre, W. Shepard, M. Roth, M. Leng and C. Zelwer, "Crystal structure of a double-stranded DNA containing a cisplatin interstrand cross-link at 1.63 A resolution: hydration at the platinated site", Nucleic Acids Res , 1999, 27 , 1837
  • 8.
  • 9.
  • 10.
  • 11.
  • 12.
  • 13.
  • 14. Cytotoxicity Cisplatin-Resistant Tumor Lines IC 50 ( µM) Cancer cell line cisplatin 1 Chronic myelogenous leukemia K562 >80 3 Chronic myelogenous leukemia KG-1 48 2 Acute myelogenous leukemia ML-2 >80 1 Mouse melanoma B16 >80 6 Colon cancer HT-29N >80 12 Colon cancer HT29 50 8 Colon cancer HCT116 >80 9 Lung carcinoma A427 63 6 Breast carcinoma HBL100 63 6 Breast carcinoma MCF-7 71 8 Lung carcinoma CORL23/CTR >80 25 Ovarian carcinoma A2780 4 4 Ovarian carcinoma A2780/cis 40 3 Ovarian carcinoma A2780/cis90 >80 7

Hinweis der Redaktion

  1. While studying electric fields and growth of E. Coli/// Rosenberg 1964 Group VIIIb transition metal compounds inhibit cell division 1-10ppm Growth not affected Components of the experimental medium were electrolyzed and tested for the presence of oxidizing agents by reacting with KI/starch solutions. Positive results were found for NH4Cl. NH4)2PtCl6 was formed to be the active agent.
  2. the trans effect is the labilization of ligands trans to certain other ligands, which can thus be regarded as trans directing ligands.
  3. F. Coste, J. M. Malinge, L. Serre, W. Shepard, M. Roth, M. Leng and C. Zelwer, "Crystal structure of a double-stranded DNA containing a cisplatin interstrand cross-link at 1.63 A resolution: hydration at the platinated site", Nucleic Acids Res , 1999, 27 , 1837
  4. Preformed Pt- HSA (human serum albumin) administered clinically to patients there was increased survival time. Individuals with low HSA did not respond well to cisplatin Centerwall at Syracuse found using HSQC NMR N15 NMR-h1
  5. Carboplatin cyclobutane dicarboxylate decreases reactivity. Oxaliplatin for colon cancer…oxalate increases water solubility…othermechanisms unknown
  6. Many insecticides show cross resistance Increased reactivity with glutathione may reduce cytotoxicity
  7. Lead compound in future studies of Pt. compounds with hydrophobic ligands. They speculate that the structure of water molecules around adamantineamine affect reaction with glutathione and thiols.